VCYT
Neutral signalScored 2026-10-25 Drivers: Congress, trend, fundamentals. Moteurs : Congrès, tendance, fondamentaux.
Research, not advice.
À propos
Veracyte, Inc.
- Nom
- Veracyte, Inc.
- Secteur
- Healthcare
- Industrie
- Medical - Diagnostics & Research
- Bourse
- NASDAQ
- Capitalisation
- $3.8B
- Employés
- 755
- PDG
- Marc Stapley
- Site web
- https://www.veracyte.com
- Marché
- BDSXBIAFBLLNCSTLGHIMDX
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 6 864 titres (~286 203,80 $ US)
- Insiders
- Bhanji MunaHolstein Jens
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$744,408
Avg sell (VWAP, 90d window) $42.00 vs last close $48.20 (+14.8%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$662,951 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-10-19
- Liquidity
- Liquid $56,255,866/day · 20d vol
- Last synced
-
2026-10-26 21:11:05
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-19 | Bhanji Muna | Sell · S | 1,864 | $43.70 | $81,457 | Form 4 |
| 2026-09-21 | Leite John | Sell · S · 10b5-1 | 4,015 | $40.00 | $160,600 | Form 4 |
| 2026-09-14 | Holstein Jens | Sell · S · 10b5-1 | 5,000 | $40.95 | $204,747 | Form 4 |
| 2026-09-04 | Chambers Rebecca | Sell · S · 10b5-1 | 1,175 | $43.71 | $51,364 | Form 4 |
| 2026-09-04 | Febbo Phillip G. | Sell · S · 10b5-1 | 2,705 | $43.66 | $118,105 | Form 4 |
| 2026-09-04 | McGuire Annie | Sell · S · 10b5-1 | 1,100 | $43.67 | $48,039 | Form 4 |
| 2026-09-01 | Bhanji Muna | Sell · S · 10b5-1 | 1,864 | $42.97 | $80,096 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-03-03 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2026-02-18 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2025-11-12 | Gilbert Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2025-06-16 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2023-10-16 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
| 2023-09-15 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2023-04-10 | Daniel Goldman | Sale | $1,001 - $15,000 |
| 2020-12-23 | Gilbert Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2020-12-10 | Gilbert Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2020-12-08 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2020-10-29 | Gilbert Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2020-01-17 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2019-12-24 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2019-12-12 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2019-12-06 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
Signal
Neutral signalScored 2026-10-25 Drivers: Congress, trend, fundamentals. Moteurs : Congrès, tendance, fondamentaux.
VCYT presents a compelling combination of strong financial health (liquidity score 95, fundamentals trend 85) and a meaningful clinical/reimbursement catalyst stack ahead of Q3 earnings on Nov 4, including positive…
The first sentence of the analysis written for VCYT on 2026-10-25 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Narrative Supports a bullish reading. Stored narrative reading is in the bullish band
- Congress Supports a bullish reading. 2 purchase disclosures year to date
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Supports a bullish reading. Current ratio 8.15 · operating margin 14%
Suggested stop 42.04, nearest stored support minus 0.5 ATR(12.8% under the last close). Reward/risk to the next stored resistance is 0.13. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Recent news
- 2026-10-23 Phase III Trial Shows Veracyte''s Decipher Prostate Test Can Predict Benefit from Adding Abiraterone to Treatment in Very High-Risk Prostate Cancer STAMPEDE study analysis providing new predictive evidence in clinically very high-risk, nonmetastatic disease to be presented at ESMO STAMPEDE study analysis providing new predictive evidence in clinically very high-risk, nonmetastatic disease to be presented at ESMO
- 2026-10-21 Will Veracyte (VCYT) Beat Estimates Again in Its Next Earnings Report? Veracyte (VCYT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 2026-10-20 Veracyte (NASDAQ:VCYT) Stock Price Breaks Below 200 Day Moving Average – Should You Sell? Veracyte, Inc. (NASDAQ: VCYT - Get Free Report)''s share price crossed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $45.25 and traded as low as $43.45. Veracyte shares last traded at $43.80, with a volume of 725,427 shares. Analyst Ratings Changes Several analysts recently issued reports on
- 2026-10-19 Six Studies to Highlight Veracyte''s Genomic Tests Across Breast, Prostate and Bladder Cancer at ESMO 2026 SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that six studies involving its genomic tests will be presented at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27 in Madrid, Spain.
- 2026-10-16 Veracyte Secures Medicare Reimbursement for Prosigna Breast Risk of Recurrence Test Milestone supports broader U.S. adoption of Prosigna and expands access for eligible patients with early-stage breast cancer Milestone supports broader U.S. adoption of Prosigna and expands access for eligible patients with early-stage breast cancer
- 2026-10-14 Veracyte to Release Third Quarter 2026 Financial Results on November 4, 2026 SOUTH SAN FRANCISCO, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the third quarter 2026 after the close of market on Wednesday, November 4, 2026.
- 2026-09-29 Phase III Trial Demonstrates Veracyte''s Decipher Prostate Test Predicts Benefit from Adding Hormone Therapy to Radiation SOUTH SAN FRANCISCO, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced that new findings from a retrospective ancillary analysis of the randomized phase III NRG/RTOG 0815 trial will be presented at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting.
- 2026-09-25 Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026 Six oral presentations and two posters will highlight Decipher''s prognostic and predictive value in identifying patients'' risk of progression and likelihood of benefiting from treatment intensification Six oral presentations and two posters will highlight Decipher''s prognostic and predictive value in identifying patients'' risk of progression and likelihood of benefiting from treatment intensification
- 2026-09-25 Veracyte (VCYT) Surges 10.8%: Is This an Indication of Further Gains? Veracyte (VCYT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn''t suggest further strength down the road.
- 2026-09-23 Veracyte (NASDAQ:VCYT) Insider John Leite Sells 4,015 Shares Veracyte, Inc. (NASDAQ: VCYT - Get Free Report) insider John Leite sold 4,015 shares of Veracyte stock in a transaction dated Monday, September 21st. The shares were sold at an average price of $40.00, for a total transaction of $160,600.00. Following the sale, the insider owned 124,329 shares in the company, valued at approximately $4,973,160. This
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 69.6% | 66.9% | 68.7% | 65.7% | 66.1% | |
| Ebit Margin | 13.2% | 5.8% | -21.2% | -12.2% | -37.1% | |
| Ebitda Margin | 17.3% | 11.0% | -13.7% | -3.5% | -28.2% | |
| Operating Profit Margin | 14.3% | 3.6% | -23.8% | -13.9% | -37.3% | |
| Pretax Profit Margin | 13.2% | 5.8% | -21.2% | -12.3% | -37.2% | |
| Continuous Operations Profit Margin | 12.8% | 5.4% | -20.6% | -12.3% | -34.4% | |
| Net Profit Margin | 12.8% | 5.4% | -20.6% | -12.3% | -34.4% | |
| Bottom Line Profit Margin | 12.8% | 5.4% | -20.6% | -12.3% | -34.4% | |
| Current Ratio | 8.148 | 4.734 | 4.664 | 3.971 | 3.790 | |
| Quick Ratio | 7.805 | 4.458 | 4.401 | 3.743 | 3.615 | |
| Solvency Ratio | 0.910 | 0.384 | -0.667 | -0.131 | -0.613 | |
| Cash Ratio | 6.049 | 3.041 | 3.534 | 2.463 | 2.700 | |
| Price To Earnings Ratio | 50.119 | 123.750 | -26.971 | -46.529 | -37.117 | |
| Price To Earnings Growth Ratio | 0.308 | -0.942 | -0.270 | 0.861 | -0.544 | |
| Forward Price To Earnings Growth Ratio | 0.308 | -0.942 | -0.270 | 0.861 | -0.544 | |
| Price To Earnings Diluted Ratio | 51.341 | 127.742 | -26.971 | -46.529 | -37.117 | |
| Price To Earnings Diluted Growth Ratio | 0.312 | -0.980 | -0.270 | 0.861 | -0.544 | |
| Price To Book Ratio | 2.526 | 2.576 | 1.914 | 1.579 | 2.551 | |
| Price To Sales Ratio | 6.397 | 6.795 | 5.535 | 5.726 | 12.742 | |
| Price To Free Cash Flow Ratio | 26.126 | 47.467 | 58.330 | -1,674.421 | -75.603 | |
| Price To Operating Cash Flow Ratio | 24.272 | 40.332 | 45.191 | 225.330 | -88.456 | |
| Debt To Assets Ratio | 0.028 | 0.039 | 0.011 | 0.013 | 0.016 | |
| Debt To Equity Ratio | 0.030 | 0.043 | 0.012 | 0.014 | 0.017 | |
| Debt To Capital Ratio | 0.029 | 0.041 | 0.012 | 0.014 | 0.017 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.074 | 1.106 | 1.068 | 1.076 | 1.083 | |
| Working Capital Turnover Ratio | 1.432 | 1.721 | 1.759 | 1.625 | 0.816 | |
| Operating Cash Flow Ratio | 2.274 | 0.955 | 0.722 | 0.120 | -0.493 | |
| Operating Cash Flow Sales Ratio | 0.264 | 0.168 | 0.122 | 0.025 | -0.144 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.929 | 0.850 | 0.775 | -0.135 | 1.170 | |
| Debt Service Coverage Ratio | 0.000 | 23,799.500 | -3,146.733 | -52.697 | -40.738 | |
| Interest Coverage Ratio | 0.000 | 8,071.000 | -5,719.667 | -207.480 | -339.846 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | -28.058 | |
| Operating Cash Flow Coverage Ratio | 3.437 | 1.480 | 3.501 | 0.512 | -1.677 | |
| Capital Expenditure Coverage Ratio | 14.086 | 6.653 | 4.440 | 0.881 | -5.882 | |
| Dividend Paid And Capex Coverage Ratio | 14.086 | 6.653 | 4.440 | 0.881 | -5.882 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 33.314 | 57.727 | -36.322 | -151.280 | -42.752 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 69.6% | ▲2.7% | ▲2.2% |
| Ebit Margin | 13.2% | ▲7.4% | ▲23.5% |
| Ebitda Margin | 17.3% | ▲6.3% | ▲20.7% |
| Operating Profit Margin | 14.3% | ▲10.7% | ▲25.7% |
| Pretax Profit Margin | 13.2% | ▲7.4% | ▲23.5% |
| Continuous Operations Profit Margin | 12.8% | ▲7.4% | ▲22.7% |
| Net Profit Margin | 12.8% | ▲7.4% | ▲22.7% |
| Bottom Line Profit Margin | 12.8% | ▲7.4% | ▲22.7% |
| Current Ratio | 8.148 | ▲3.414 | ▲3.087 |
| Quick Ratio | 7.805 | ▲3.348 | ▲3.001 |
| Solvency Ratio | 0.910 | ▲0.526 | ▲0.933 |
| Cash Ratio | 6.049 | ▲3.009 | ▲2.492 |
| Price To Earnings Ratio | 50.119 | ▼-73.631 | ▲37.469 |
| Price To Earnings Growth Ratio | 0.308 | ▲1.250 | ▲0.426 |
| Forward Price To Earnings Growth Ratio | 0.308 | ▲1.250 | ▲0.426 |
| Price To Earnings Diluted Ratio | 51.342 | ▼-76.400 | ▲37.648 |
| Price To Earnings Diluted Growth Ratio | 0.312 | ▲1.292 | ▲0.436 |
| Price To Book Ratio | 2.526 | ▼-0.049 | ▲0.297 |
| Price To Sales Ratio | 6.397 | ▼-0.397 | ▼-1.042 |
| Price To Free Cash Flow Ratio | 26.127 | ▼-21.340 | ▲349.747 |
| Price To Operating Cash Flow Ratio | 24.272 | ▼-16.061 | ▼-25.062 |
| Debt To Assets Ratio | 0.028 | ▼-0.011 | ▲0.007 |
| Debt To Equity Ratio | 0.030 | ▼-0.013 | ▲0.007 |
| Debt To Capital Ratio | 0.029 | ▼-0.012 | ▲0.007 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.074 | ▼-0.032 | ▼-0.007 |
| Working Capital Turnover Ratio | 1.432 | ▼-0.289 | ▼-0.038 |
| Operating Cash Flow Ratio | 2.274 | ▲1.319 | ▲1.558 |
| Operating Cash Flow Sales Ratio | 0.264 | ▲0.095 | ▲0.176 |
| Free Cash Flow Operating Cash Flow Ratio | 0.929 | ▲0.079 | ▲0.211 |
| Debt Service Coverage Ratio | 0.000 | ▼-23799.500 | ▼-4111.866 |
| Interest Coverage Ratio | 0.000 | ▼-8071.000 | ▼-360.801 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | ▲5.612 |
| Operating Cash Flow Coverage Ratio | 3.437 | ▲1.957 | ▲1.987 |
| Capital Expenditure Coverage Ratio | 14.086 | ▲7.432 | ▲10.050 |
| Dividend Paid And Capex Coverage Ratio | 14.086 | ▲7.432 | ▲10.050 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 33.314 | ▼-24.413 | ▲61.177 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $3.31B | $3.03B | $2.00B | $1.70B | $2.80B | |
| Enterprise value | $2.99B | $2.84B | $1.79B | $1.56B | $2.64B | |
| EV / Sales | 5.77x | 6.37x | 4.97x | 5.25x | 12.04x | |
| EV / Op. cash flow | 21.90x | 37.82x | 40.58x | 206.81x | -83.58x | |
| EV / Free cash flow | 23.58x | 44.52x | 52.38x | -1536.82x | -71.43x | |
| EV / EBITDA | 33.31x | 57.73x | -36.32x | -151.28x | -42.75x | |
| Net debt / EBITDA | -3.60x | -3.83x | 4.12x | 13.54x | 2.50x | |
| Current ratio | 8.15x | 4.73x | 4.66x | 3.97x | 3.79x | |
| Income quality | 2.05x | 3.11x | -0.59x | -0.21x | 0.42x | |
| Graham number | $18 | $10 | — | — | — | |
| Graham net-net | $5 | $3 | $3 | $2 | $2 | |
| Tax burden | 97.3% | 93.8% | 97.1% | 100.4% | 92.5% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.5% | 100.3% | |
| Working capital | $428.4M | $293.6M | $224.4M | $186.0M | $179.0M | |
| Invested capital | $1.34B | $1.21B | $1.05B | $1.09B | $1.12B | |
| Return on assets | 4.7% | 1.9% | -6.7% | -3.2% | -6.4% | |
| Operating ROA | 5.5% | 1.3% | -7.6% | -3.5% | -10.0% | |
| Return on tangible assets | 12.1% | 5.3% | -23.0% | -12.8% | -27.3% | |
| Return on equity | 5.1% | 2.1% | -7.1% | -3.4% | -6.9% | |
| Return on invested capital | 5.3% | 1.2% | -7.9% | -3.7% | -6.7% | |
| Return on capital employed | 5.5% | 1.3% | -8.1% | -3.8% | -7.3% | |
| Earnings yield | 2.0% | 0.8% | -3.7% | -2.2% | -2.7% | |
| Free cash flow yield | 3.8% | 2.1% | 1.7% | -0.1% | -1.3% | |
| Capex / Op. cash flow | 7.1% | 15.0% | 22.5% | 113.5% | -17.0% | |
| Capex / Depreciation | 45.2% | 48.1% | 36.6% | 33.0% | 27.4% | |
| Capex / Sales | 1.9% | 2.5% | 2.8% | 2.9% | 2.4% | |
| SG&A / Sales | 40.8% | 46.2% | 51.0% | 58.7% | 82.5% | |
| R&D / Sales | 13.7% | 15.5% | 15.9% | 13.7% | 13.6% | |
| Stock comp / Sales | 8.4% | 8.1% | 9.2% | 9.0% | 10.3% | |
| Intangibles / Total assets | 60.9% | 65.2% | 71.0% | 75.3% | 76.7% | |
| Days sales outstanding | 32d | 38d | 41d | 54d | 69d | |
| Days payables outstanding | 11d | 21d | 42d | 43d | 61d | |
| Operating cycle | 79d | 92d | 93d | 106d | 124d | |
| Cash conversion cycle | 69d | 71d | 51d | 63d | 63d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years